Enzymotec is Granted with a New Japanese Patent for Lyso-PC

Enzymotec continues to invest efforts in order to expand its variety of products especially the phospholipids based ones. The company believes in offering its customers diverse of opportunities enabling to cover all kind of applications.

23/02/09 Enzymotec has received the Japanese patent office approval for its’ production process of Lyso-Phospholipids. The patent entitled “enzymatic process for the production of predetermined 1-acyl-2 lyso and 1,2-diacylated glycerophospholipids and their synthetic or natural analogues” (JP 4216082) was granted on 14.11.08 following approvals from the Israel and US patent offices. The glycerophospholipids referred in the patent include phosphatidyl choline, phosphatidyl ethanol amine, phosphatidyl serine , phosphatidylinositol and phosphatidylglycerol.

Enzymotec continues to invest efforts in order to expand its variety of products especially the phospholipids based ones. The company believes in offering its customers diverse of opportunities enabling to cover all kind of applications.

Enzymotec is a developer and manufacturer of innovative, lipid-based biofunctional solutions for orthomolecular medicine, dietary supplements and advanced infant nutrition. Key products are: Sharp-PS line of products- phosphatidylserine based ingredients for cognitive improvement, InFat - structured fat for infant formulas, CardiaBeat offering a broad health effect to reduce CVD risks and Krill Oil+.